Compare Fortinet Inc (FTNT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Repligen Corporation Common Stock — how do they compare? Fortinet Inc trades at $180.93 (market cap $135.04B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Fortinet Inc is far larger — about 11.9× Repligen Corporation Common Stock's market cap, and Fortinet Inc is more actively traded (3,955,126 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Repligen Corporation Common Stock for 0 Days on average.
| FTNT | RGEN | |
|---|---|---|
Market Cap | $135.04B | $11.31B |
Volume | 3,955,126 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $194.75 | $194.57 |
52-Week Low | $75.23 | $102.87 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $131.47B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $190.76, down 1.13% on the day but remains in a bullish technical trend with strong support near $191. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.90 surpassing the $0.746 estimate. Revenue growth is steady, reaching $6.80B in 2025, while profitability metrics like a 28.17% net income margin and 117.44% ROE highlight operational efficiency. Recent news highlights AI-driven cybersecurity demand and a 52-week high, reflecting positive momentum.
The outlook for FTNT is positive, driven by cybersecurity tailwinds and superior product economics, but high valuation ratios (P/E of 67.41, P/S of 18.95) pose risks if growth slows. Analyst consensus is mixed with 42% buy ratings, and the stock trades above the $160.24 price target, suggesting limited near-term upside. Key risks include competitive pressures and execution challenges in sustaining high growth rates.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
